Home › Trials › NCT03869619

Real-world data collection for lymphoma and patient survival

REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS

Observational Hospices Civils de Lyon · NCT03869619

This study is trying to gather real-life information from lymphoma patients to see how different factors affect their treatment success and long-term survival.

Quick facts

Study typeObservational
Enrollment6000 (estimated)
Ages18 Years and up
SexAll
SponsorHospices Civils de Lyon Academic / other
Drugs / interventionscyclophosphamide
Locations37 sites (Arras and 36 other locations)
Trial IDNCT03869619 on ClinicalTrials.gov

What this trial studies

The REALYSA cohort is an observational platform designed to gather real-world epidemiological data on various types of lymphoma, including Diffuse Large B-cell Lymphoma and Follicular Lymphoma. This study aims to enhance prognostic understanding by integrating clinical, biological, and epidemiological data to identify factors influencing treatment outcomes and long-term survivorship. It also seeks to document treatment effectiveness in real-life settings and address socio-economic impacts on patients. By following lymphoma patients over time, the study will provide insights into quality of life and potential long-term sequelae.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 who have been diagnosed with specific types of lymphoma within the last six months.

Not a fit: Patients who have already received anti-lymphoma treatment or have certain excluded lymphoma subtypes will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve understanding of lymphoma prognosis and treatment effectiveness, ultimately enhancing patient care.

How similar studies have performed: Other studies utilizing real-world data in oncology have shown promise, suggesting that this approach could yield valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Signature of the consent form for participation in the REALYSA cohort
* Aged over 18 at the time of inclusion
* Diagnosed with lymphoma in the last 6 months (180 days)
* Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma

Exclusion Criteria:

* Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
* Documented HIV infection
* Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:

  * Chronic lymphocytic leukemia/small lymphocytic lymphoma
  * Hairy cell leukemia and variant
  * Lymphoplasmacytic lymphoma
  * Waldenström macroglobulinemia
  * Primary DLBCL of the central nervous system (CNS)
  * T-cell large granular lymphocytic leukemia
  * Chronic lymphoproliferative disorder of NK cells
  * Mycosis fungoides
  * Sézary syndrome
  * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
  * Post-transplant lymphoproliferative disorders (PTLD)

Where this trial is running

Arras and 36 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Diffuse Large B LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaT-cell LymphomaHodgkin's LymphomaBurkitt Lymphoma)lymphoma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.